RAPT Therapeutics Reports Second Quarter 2021 Financial Results Portfolio News / By Karina Tin August 11, 2021 RAPT Therapeutics Reports Second Quarter 2021 Financial Results Read More »
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin August 11, 2021 Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Read More »
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration Portfolio News / By Karina Tin August 11, 2021 Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration Read More »
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Portfolio News / By Karina Tin August 10, 2021 ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Read More »
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth Portfolio News / By Karina Tin August 5, 2021 Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth Read More »
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Portfolio News / By Karina Tin August 5, 2021 NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Read More »
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer Portfolio News / By Karina Tin August 4, 2021 eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer Read More »
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin August 3, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Read More »
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent Portfolio News / By Karina Tin July 22, 2021 eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent Read More »
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Portfolio News / By Karina Tin July 22, 2021 NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Read More »
